Release Date: 20-Aug-2024
The mechanisms of action of TIGIT antibodies in immune modulation are intricate and pivotal for understanding their therapeutic potential. TIGIT, an immune checkpoint receptor, inhibits immune cell activity upon binding to its ligands, CD155 and CD112. TIGIT antibodies work by blocking this interaction, thereby lifting the inhibition and enhancing immune responses against tumors.
Download Report
One primary mechanism involves the direct blockade of TIGIT on T cells. TIGIT, when engaged, transmits inhibitory signals that reduce T cell proliferation and cytokine production. By preventing TIGIT from binding to its ligands, TIGIT antibodies reinvigorate T cell activity. This reactivation leads to increased production of effector cytokines like IFN-andgamma; and TNF-andalpha;, which are crucial for anti-tumor immunity.
Another critical mechanism is the enhancement of NK cell function. NK cells, essential for the innate immune response against tumors, also express TIGIT. Upon binding to CD155 and CD112, TIGIT delivers inhibitory signals that suppress NK cell cytotoxicity. TIGIT antibodies, by blocking this interaction, restore the cytotoxic function of NK cells. This restoration is vital for directly killing tumor cells and producing cytokines that recruit and activate other immune cells within the tumor microenvironment.
TIGIT antibodies also impact the regulatory T cells (Tregs) that express high levels of TIGIT. Tregs play a significant role in maintaining immune tolerance and can suppress anti-tumor immune responses. By blocking TIGIT, TIGIT antibodies may reduce the suppressive function of Tregs, thereby enhancing the overall immune response against the tumor.
Furthermore, TIGIT antibodies indirectly modulate the immune landscape within the tumor microenvironment. By blocking TIGIT, these antibodies can increase the expression of co-stimulatory molecules and decrease the expression of inhibitory molecules on immune cells. This shift enhances the overall activation state of immune cells, making them more effective at recognizing and attacking tumor cells.
The ability of TIGIT antibodies to synergize with other immune checkpoint inhibitors like PD-1 and CTLA-4 also highlights their complex mechanisms of action. Combining TIGIT blockade with these inhibitors can lead to a more comprehensive activation of the immune system. PD-1 and CTLA-4 inhibitors primarily target different pathways, and their combined use with TIGIT antibodies can result in a more robust and sustained anti-tumor response. This synergy is particularly evident in preclinical models, where combination therapies have shown superior efficacy compared to monotherapies.
In summary, the mechanisms of action of TIGIT antibodies in immune modulation are multifaceted and involve direct reactivation of T cells and NK cells, reduction of Treg-mediated suppression, and overall enhancement of immune cell activity within the tumor microenvironment. By understanding these mechanisms, researchers can better optimize TIGIT antibody therapies, develop combination strategies, and identify patients most likely to benefit from these treatments.